Welcome to our dedicated page for Cardiol Therapeu SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Cardiol Therapeutics Inc. (CRDL) provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Cardiol files reports on Form 6-K under the Securities Exchange Act of 1934, which transmit key documents such as financial statements, management’s discussion and analysis, and material news releases related to its operations as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease.
Among the filings, investors can find condensed interim consolidated financial statements and accompanying management’s discussion and analysis for specified periods, as referenced in Form 6-K submissions. These documents outline operating results, research and development spending, and other financial information relevant to Cardiol’s clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis.
Form 6-K filings also incorporate news releases that describe important corporate events. Examples include announcements of private placement financings that support the pivotal Phase III MAVERIC trial and the development of CRD-38, updates on clinical trial milestones such as database lock and topline results from ARCHER, and disclosures about intellectual property developments like the U.S. patent allowance for cannabidiol compositions in heart conditions. Additional exhibits may include reports of exempt distributions and material change reports filed in connection with financings or other significant events.
On Stock Titan, these SEC filings are organized chronologically and can be paired with AI-powered summaries that explain the main points of each document in clear language. Users can quickly scan Form 6-K submissions, understand which exhibits are attached—such as financial statements, certifications of interim filings, or specific news releases—and identify items relevant to Cardiol’s clinical-stage cardiovascular pipeline, regulatory designations, and capital-raising activities.
Cardiol Therapeutics Inc. reports continued progress in its pivotal Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis. U.S. patient enrollment has reached 75%, and the Company plans to activate up to seven additional U.S. clinical centers to support recruitment.
The MAVERIC trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 110 patients, with target recruitment anticipated by the end of Q2 2026 and potential extension into Q3. MAVERIC builds on Phase II data showing rapid and sustained reductions in pericarditis pain, inflammation, and recurrence rates.
Cardiol highlights the participation of premier cardiovascular research institutions and notes that CardiolRx™ has received U.S. FDA Orphan Drug Designation for pericarditis. Beyond MAVERIC, the Company references prior Phase II ARCHER data in acute myocarditis and ongoing development of its subcutaneous candidate CRD-38 for inflammatory heart disease.
Cardiol Therapeutics Inc. filed a report highlighting a live interview where its CEO will discuss key clinical programs. The session on X, hosted by Barchart, will cover the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis, recent Phase II ARCHER results in acute myocarditis, and the Company’s next-generation heart failure candidate CRD-38. The filing also reiterates that Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for serious heart diseases, with CardiolRx™ granted U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics Inc. has scheduled its next annual general meeting of securityholders. The meeting will be held on June 24, 2026, with a record date of May 7, 2026 for both notice of meeting and voting rights, and for determining beneficial ownership.
The meeting will involve holders of Class A Common shares. The company will use notice-and-access procedures for both registered and beneficial holders and will pay for delivery of proxy materials to objecting beneficial owners. Odyssey Trust Company is acting as agent for Cardiol in this process.
Cardiol Therapeutics provides a year-end 2025 operations update highlighting major clinical, IP, and financing milestones. The Company advanced its pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis past 50% enrollment toward full enrollment expected in Q2 2026. Positive Phase II ARCHER data in 109 acute myocarditis patients showed CardiolRx™ significantly reduced left ventricular mass by 9.2g and improved multiple cardiac MRI endpoints, with full results published in ESC Heart Failure. Cardiol progressed its next-generation drug CRD-38 through IND-enabling work, received a U.S. patent allowance protecting CardiolRx™ and CRD-38 for major cardiac indications to October 2040, strengthened its Board, and raised an aggregate $31 million, extending cash runway into Q4 2027.
Cardiol Therapeutics Inc. files its Annual Report on Form 40-F, providing its audited financial statements, Management’s Discussion and Analysis, and related certifications for the fiscal year ended December 31, 2025. The filing states 100,257,009 shares outstanding as of the close of the period and confirms management concluded internal controls were effective as of December 31, 2025.
The report discloses audit fees of $403,570 for the fiscal year ended December 31, 2025 and notes the company is a Canadian foreign private issuer preparing financials under IFRS with amounts reported in Canadian dollars (exchange rate U.S.$1.00 = CDN$1.37 on December 31, 2025).
Cardiol Therapeutics Inc. filed a Form 6-K highlighting its upcoming presentation at the TD Cowen 46th Annual Health Care Conference in Boston. Company management will present on March 4, 2026, at 10:30 a.m. EST, with a live and replay webcast available in the Investors section of its website.
The filing also outlines Cardiol’s late-stage pipeline. Lead candidate CardiolRx™ targets inflammasome pathway activation in heart diseases such as recurrent pericarditis, acute myocarditis, and heart failure. Cardiol has completed Phase II studies in recurrent pericarditis and acute myocarditis and is conducting a pivotal Phase III trial in recurrent pericarditis, which has U.S. FDA Orphan Drug Designation.
Cardiol is additionally developing CRD-38, a novel subcutaneous formulation for inflammatory heart disease, including heart failure, a major cause of death and hospitalization with U.S. healthcare costs noted as exceeding US$30 billion per year.
Cardiol Therapeutics filed a 6-K to highlight newly published results from its Phase II ARCHER study of CardiolRx in acute myocarditis. The randomized, double-blind, placebo-controlled trial in 109 patients showed CardiolRx produced a significant reduction in left ventricular mass versus placebo (-9.2 g; p=0.0117), decreased left atrial remodelling, and favorable trends across multiple inflammation markers, while remaining safe and well tolerated. Reduction in left ventricular mass is described as consistent with decreased myocardial edema and inflammatory burden and better clinical outcomes in myocarditis. Management says these biological signals support the ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis and reinforce CardiolRx’s potential as an anti-inflammatory, anti-fibrotic therapy for inflammatory heart diseases.
Cardiol Therapeutics Inc. entered into an underwriting agreement for a bought-deal private placement of 11,423,078 units at $1.30 per unit, for aggregate gross proceeds of $14,850,001.40. Each unit consists of one common share and one-half common share purchase warrant.
Each whole warrant allows the holder to buy one additional common share at $1.75 until January 23, 2028, potentially adding future equity if exercised. Canaccord Genuity Corp. acts as sole underwriter and bookrunner and will receive a cash commission equal to 6% of gross proceeds, plus reimbursed expenses, under Canadian listed issuer financing and other prospectus exemptions.
MMCAP International Inc. SPC and Asset Management Inc. have disclosed a significant passive stake in Cardiol Therapeutics Inc. They report beneficial ownership of 17,451,746 Class A Common Shares, representing 14.9% of the class as of January 23, 2026.
This position includes 11,740,207 Class A Common Shares and 5,711,539 additional Class A Common Shares underlying warrants exercisable within 60 days. The shares are held through a private investment fund managed by Asset Management Inc., and both parties state the holdings are not for the purpose of influencing control of Cardiol Therapeutics.
Cardiol Therapeutics Inc. entered into a bought deal private placement with Canaccord Genuity Corp., which agreed to purchase for resale 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million. The company granted the underwriter an option to buy up to an additional 1,038,462 units at the same price to raise up to a further $1,350,000 in gross proceeds.
Each unit consists of one common share and one-half of one warrant, with each whole warrant exercisable at $1.75 per share for 24 months from issuance. Cardiol plans to use the net proceeds to advance its research and clinical development programs, and for general and administrative expenses, working capital, and other expenses. Closing is targeted on or about January 23, 2026, subject to approvals, including TSX approval and execution of an underwriting agreement.